In late October, Canadian Nuclear Laboratories (CNL) and TRIUMF announced that they had completed the first joint production run of actinium-225, a rare medical isotope that shows great promise as the basis for new, cutting-edge cancer therapies. This accomplishment is a major milestone in making high-purity actinium-225 more widely available for use in critical clinical trials. It is produced using TRIUMF’s high-energy cyclotron in Vancouver and is processed at CNL’s Chalk River Laboratories.

Read more [here](#).

**Canadian companies successfully produce “rarest drug on Earth”**

**CNL & TRIUMF successfully produce rare medical isotope that could revolutionize fight against cancer**

In late October, Canadian Nuclear Laboratories (CNL) and TRIUMF announced that they had completed the first joint production run of actinium-225, a rare medical isotope that shows great promise as the basis for new, cutting-edge cancer therapies. This accomplishment is a major milestone in making high-purity actinium-225 more widely available for use in critical clinical trials. It is produced using TRIUMF’s high-energy cyclotron in Vancouver and is processed at CNL’s Chalk River Laboratories.

Read more [here](#).